Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.

Schmid, Peter; Zaiss, Matthias; Harper-Wynne, Catherine; Ferreira, Marta; Dubey, Sidharth; Chan, Stephen; Makris, Andreas; Nemsadze, Gia; Brunt, Adrian M; Kuemmel, Sherko; Ruiz, Isabel; Perelló, Antonia; Kendall, Anne; Brown, Janet; Kristeleit, Hartmut; Conibear, John; Saura, Cristina; Grenier, Julien; Máhr, Károly; Schenker, Michael; Sohn, Joohyuk; Lee, Keun Seok; Shepherd, Christopher J; Oelmann, Elisabeth; Sarker, Shah-Jalal; Prendergast, Aaron; Marosics, Patricia; Moosa, Atiyyah; Lawrence, Cheryl; Coetzee, Carike; Mousa, Kelly; Cortés, Javier

Schmid, Peter; Zaiss, Matthias; Harper-Wynne, Catherine; Ferreira, Marta; Dubey, Sidharth; Chan, Stephen; Makris, Andreas; Nemsadze, Gia; Brunt, Adrian M; Kuemmel, Sherko; Ruiz, Isabel; Perelló, Antonia; Kendall, Anne; Brown, Janet; Kristeleit, Hartmut; Conibear, John; Saura, Cristina; Grenier, Julien; Máhr, Károly; Schenker, Michael; Sohn, Joohyuk; Lee, Keun Seok; Shepherd, Christopher J; Oelmann, Elisabeth; Sarker, Shah-Jalal; Prendergast, Aaron; Marosics, Patricia; Moosa, Atiyyah; Lawrence, Cheryl; Coetzee, Carike; Mousa, Kelly; Cortés, Javier.

Afiliación

Schmid P; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Zaiss M; Oncology-Clinical, Barts Health National Health Service Trust, London, United Kingdom.
Harper-Wynne C; Praxis fuer Interdisziplinaere Onkologie, Freiburg, Germany.
Ferreira M; Kent Oncology Centre, Maidstone and Tunbridge Wells National Health Service Trust, Tunbridge Wells, United Kingdom.
Dubey S; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.
Chan S; Oncology, Derriford Hospital, Plymouth Hospitals National Health System Trust, Plymouth, United Kingdom.
Makris A; Oncology-Clinical, Nottingham University Hospitals National Health System Trust, Nottingham, United Kingdom.
Nemsadze G; Mount Vernon Cancer Centre, East & North Herts National Health System Trust, London, United Kingdom.
Brunt AM; Institute of Clinical Oncology, Tbilisi, Republic of Georgia.
Kuemmel S; Cancer Centre, University Hospitals of North Midlands National Health System Trust, Stoke-on-Trent, United Kingdom.
Ruiz I; Kliniken Essen-Mitte, Essen, Germany.
Perelló A; Hospital Universitario Sant Joan De Reus, Tarragona, Spain.
Kendall A; Hospital Son Espases, Palma, Spain.
Brown J; Cancer Services, Great Western Hospitals National Health System Foundation Trust, Swindon, United Kingdom.
Kristeleit H; Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, United Kingdom.
Conibear J; Medical Oncology, Queen Elizabeth Hospital, Woolwich, Lewisham and Greenwich National Health System Trust, London, United Kingdom.
Saura C; Oncology-Clinical, Barts Health National Health Service Trust, London, United Kingdom.
Grenier J; Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Research Group, Vall d'Hebron University Hospital, Barcelona, Spain.
Máhr K; Institut Sainte Catherine, Avignon, France.
Schenker M; Zala County Hospital, Zalaegerszeg, Hungary.
Sohn J; Sf Nectarie Oncology Center Societate cu Raspundere Limitata, Craiova, Dolj, Romania.
Lee KS; Yonsei University Health System, Seoul, Republic of Korea.
Shepherd CJ; National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea.
Oelmann E; Oncology Translational Medicine Unit, Innovative Medicines and Early Drug Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
Sarker SJ; Oncology Translational Medicine Unit, Innovative Medicines and Early Drug Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
Prendergast A; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Marosics P; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Moosa A; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Lawrence C; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Coetzee C; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Mousa K; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Cortés J; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.

JAMA Oncol ; 5(11): 1556-1564, 2019 Nov 01.

Article en En | MEDLINE | ID: mdl-31465093

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: JAMA Oncol Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google